Tzield Approved to Preserve Insulin Production
Quick Facts
What Did the FDA Approve Tzield to Treat?
Stage 3 type 1 diabetes begins when autoimmune destruction of pancreatic beta cells causes clinically significant insulin deficiency and high blood glucose. Tzield, the brand name for teplizumab-mzwv, is a monoclonal antibody that targets CD3 on T cells and modifies the immune response involved in beta-cell destruction.
The expanded indication represents an important shift toward treating the underlying autoimmune process soon after diagnosis. Tzield does not cure type 1 diabetes or eliminate the need for insulin, glucose monitoring, nutrition planning and emergency preparation for severe hypoglycemia or diabetic ketoacidosis.
How Can Tzield Preserve Natural Insulin Production?
Clinical trials evaluate remaining beta-cell function by measuring C-peptide, which is released when the pancreas produces insulin. Research in children and adolescents with recently diagnosed type 1 diabetes found that teplizumab helped preserve C-peptide responses compared with placebo, providing evidence that immune therapy can influence disease progression after clinical diagnosis.
Preserving even partial insulin production may support more stable glucose regulation, although individual benefits vary. The treatment should therefore be understood as a disease-modifying addition to standard care rather than a replacement for insulin therapy. Longer follow-up is needed to determine how durable the effect is and which patients benefit most.
What Should Families Know About Tzield Safety?
The FDA prescribing information warns about cytokine-release syndrome, serious infections, lymphopenia and hypersensitivity reactions. Clinicians assess patients before treatment, review vaccination status and monitor laboratory results and symptoms during the treatment course. Live vaccines may require special timing because Tzield modifies immune activity.
Families should promptly report fever, nausea, headache, rash, breathing difficulty or signs of infection. Treatment decisions should be made with a pediatric endocrinology team after considering the child's health, diabetes course, potential benefit, monitoring burden and access to an experienced infusion center.
Frequently Asked Questions
No. Tzield may preserve some remaining beta-cell function, but it does not replace insulin. Patients must continue their prescribed insulin, glucose monitoring and diabetes care plan.
Yes. Teplizumab was previously approved to delay progression from stage 2 to stage 3 type 1 diabetes in eligible patients. The expanded indication covers certain patients ages 8 to 17 who have recently reached stage 3.
No. Eligibility depends on age, timing of diagnosis, clinical status and safety considerations. A pediatric endocrinologist must determine whether treatment is appropriate.
References
- U.S. Food and Drug Administration. TZIELD (teplizumab-mzwv) prescribing information.
- Ramos EL, et al. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal of Medicine. 2023.
- WebMD. FDA Approves Tzield to Slow the Decline of Natural Insulin Production in People 8–17 Years Old With Newly Diagnosed Stage 3 Type 1 Diabetes. 2026.